Hexokinase Inhibitors
1 drugsAbout Hexokinase
Hexokinase is a ubiquitous enzyme catalyzing the first committed step of glycolysis: the phosphorylation of glucose to glucose-6-phosphate. It plays a critical role in energy metabolism, regulating cellular processes, especially in cells with high energy demands.
Currently, there is no genetic evidence directly linking hexokinase to specific diseases. However, its involvement in fundamental metabolic pathways suggests potential therapeutic applications across various disease areas.
Hexokinase is targeted by one FDA-approved drug, Fludeoxyglucose F18, a small molecule approved in 1994. This drug, marketed by PETNET, has three indications in the 'other' therapeutic area.
Top Hexokinase Drugs
PETNET is the only company with an approved drug targeting hexokinase.
The market is highly concentrated, suggesting high barriers to entry or limited commercial opportunity.
Hexokinase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Hexokinase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide a competitive advantage.
Hexokinase Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Hexokinase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 | 50% |
| Phase 2 | 4 | 3 | 0 | 1 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Hexokinase Drug Approval Timeline (1994 - 1994)
Evaluation of malignancy in patients with known or suspec...
The first and only drug targeting hexokinase was approved in 1994.
The lack of recent approvals suggests a saturated market or challenges in developing new hexokinase-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 8 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Hexokinase. A trial counts if an approved drug acting on Hexokinase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.